Bioactivx
Singapore regenerative biomaterials company spun out of A*STAR's Institute of Materials Research and Engineering and SingHealth; its Bioactiv Matrix synthetic skin substitute received HSA approval and commercially launched in September 2026 from a new Singapore manufacturing facility, targeting wound care and tissue repair.
Headquarters
Singapore
Year Founded
2023
Founders
Mickey Cheong, Peili Teo, Yew Lok Woo
Country
Singapore
Financial Information
Funding Stage
Pre-Series A
Recent Funding
$4.9M
Funding By
Cocoon Capital, ContInvest
Core Technology
Proprietary chemical synthesis platform for biosynthetic regenerative materials
Product Type
Medical Device
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Platform IP originating from A*STAR IMRE
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
A*STAR Institute of Materials Research and Engineering; SingHealth
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Synthetic off-the-shelf skin substitute manufactured in Singapore for tissue regeneration